Validation experiment designed to validate causal mechanisms targeting ASC in APP/PS1 transgenic mice (8 months old). Primary outcome: Cognitive function and AD-like pathology markers
This experiment evaluated the therapeutic potential of ASC-targeting antibodies in vivo using eight-month-old APP/PS1 transgenic mice, which are an established mouse model of Alzheimer's disease. The mice received intracerebroventricular (lateral ventricle) injections of either anti-ASC N-terminal antibodies or anti-ASC C-terminal antibodies. The study comprehensively assessed cognitive function through behavioral testing and examined multiple aspects of AD-like pathology including amyloid-β deposition, tau hyperphosphorylation, and neuroinflammation. This experiment aimed to determine whether the neuroprotective effects observed in cell culture could translate to improved outcomes in a living animal model, and whether targeting different domains of ASC would have differential therapeutic effects.
Improved cognitive function and reduced AD pathology following ASC antibody treatment
Significant improvement in cognitive performance and reduction in Aβ plaques, tau pathology, and neuroinflammation compared to control mice
No debates yet
No results recorded yet. Use POST /api/experiments/{id}/results to record a result.